Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
Author:
Affiliation:
1. Department of Gastroenterology and Hepatology, Kyoto Katsura Hospital, Japan
2. Department of Medical Oncology, Kyoto Katsura Hospital, Japan
Publisher
Japanese Society of Internal Medicine
Subject
General Medicine,Internal Medicine
Link
https://www.jstage.jst.go.jp/article/internalmedicine/60/3/60_5552-20/_pdf
Reference19 articles.
1. 1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.
2. 2. Kobayashi M, Kudo M, Izumi N, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 54: 558-570, 2019.
3. 3. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.
4. 4. Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res 49: 14-32, 2019.
5. 5. Rimassa L, Pressiani T, Merle P. Systemic treatment options in hepatocellular carcinoma. Liver Cancer 8: 427-446, 2019.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer;Investigational New Drugs;2024-05-29
2. Long-term survival and remarkably durable treatment response in a case of inoperable fibrolamellar carcinoma of the liver — a comprehensive analysis of an 8-year chemotherapeutic journey;Oncology in Clinical Practice;2024-05-24
3. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments;Clinical Journal of Gastroenterology;2023-03-01
4. Lenvatinib/regorafenib/sorafenib;Reactions Weekly;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3